Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit?
We recently published a list of the 12 Best AI Stocks to Invest in According to Reddit. In this article, we are going to take ...
EuropaWire15h
Sanofi Accelerates Chlamydia Prevention with Fast Tracked mRNA Vaccine
Sanofi’s mRNA vaccine candidate for chlamydia has been granted fast track designation by the US FDA, reflecting its promising potential to addr ...
Santé log19h
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
Paris, March 26, 2025. The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The decision was based on ...
Analysts Set Sanofi (NASDAQ:SNY) PT at $60.00
Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two research ...
Guardant Health, Inc. (NASDAQ:GH) Receives Average Rating of “Buy” from Brokerages
Guardant Health, Inc. (NASDAQ:GH – Get Free Report) has been assigned an average rating of “Buy” from the twenty analysts that are currently covering the stock, MarketBeat reports. Twenty analysts ...
Sanofi Chlamydia vaccine candidate granted fast track designation by the US FDA
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infer ...
Sanofi reports tolebrutinib submission accepted for FDA priority review
The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...
Sanofi gets priority review for its multiple sclerosis treatment by FDA
Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...
J.P. Morgan Sticks to Its Hold Rating for Sanofi (SNYNF)
In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target ...
Sanofi Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to ...
Sanofi Availability of the Q1 2025 Aide mémoire
Aide mémoire Paris, France - March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First ...
Sanofi (NASDAQ:SNY) Coverage Initiated at The Goldman Sachs Group
The Goldman Sachs Group started coverage on shares of Sanofi (NASDAQ:SNY – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The firm issued a neutral ...